Re: Tom JH Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52

被引：2

作者：

Poletajew, Slawomir ^{[1
]}

Radziszewski, Piotr ^{[1
]}

Palou, Juan ^{[2
]}

机构：

[1] Med Univ Warsaw, Dept Urol, 4 Lindleya St, PL-02005 Warsaw, Poland

[2] Univ Autonoma Barcelona, Dept Urol, Fdn Puigvert, Barcelona, Spain

来源：

EUROPEAN UROLOGY | 2017年 / 71卷 / 01期

关键词：

D O I：

10.1016/j.eururo.2016.06.042

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E29 / E30

页数：2

共 25 条

[21] Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534
Tan, Wei Shen
O'Donnell, Michael
Li, Roger
Kamat, Ashish M.
Packiam, Vignesh T.
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (01): : 164 - 165
[22] Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan, Wei Shen
Kelly, John D.
HIVEC-II Trial Team
EUROPEAN UROLOGY, 2023, 83 (01) : E29 - E30
[23] Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9
Williams, Stephen B.
Kamat, Ashish M.
EUROPEAN UROLOGY, 2016, 69 (06) : E121 - E122
[24] Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo. 2022.08.003
Tan, Wei Shen
Mustard, Connor
Kelly, John D.
EUROPEAN UROLOGY, 2023, 83 (02) : E48 - E49
[25] Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9
Sylvester, Richard
Gontero, Paolo
Oddens, Jorg
EUROPEAN UROLOGY, 2016, 69 (06) : E123 - E124

← 1 2 3 →